Transparency, Please! MBTA Resists Disclosure of Arbitration Award

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Joe Selvaggi talks with attorney for Pioneer Public Interest Law Center (PPILC) John La Liberte, about the work he did to successfully gain access to the MBTA retirement fund’s arbitration agreement after a seven-month legal struggle.

Guest:

John La Liberte has been a litigator at a prestigious Boston boutique firm for over 30 years where he has also served as the firm’s general counsel. John
decided that he wanted to join Pioneer Public Interest Law Center to do what he hoped to do when he went to law school — engage in impact litigation.
WATCH:

Recent Episodes

Hubwonk Ep. 7: Covid Testing: What went wrong, where we are & when we’ll get closer to normalcy

/
https://www.podtrac.com/pts/redirect.mp3/chtbl.com/track/G45992/feeds.soundcloud.com/stream/828394294-pioneerinstitute-hubwonk-ep-7-covid-testing-what-went-wrong-where-we-are-when-well-get-closer-to-normalcy.mp3 Join…

Hubwonk Ep. 6: COVID-19 and Commerce: Main Street’s Concerns with Governor Baker’s Course

/
In this episode of Hubwonk, Host Joe Selvaggi & Pioneer Research Analyst Rebecca Paxton to get reactions to Massachusetts Governor Charlie Baker’s phased reopening, from the leaders of two statewide business organizations, NFIB and Retailers Association of Massachusetts.

Hubwonk Ep. 5: COVID Calling: How answering the tracing phone call will move us forward

/
In this episode, Host Joe Selvaggi and Co-Host Barbara Anthony speak with the heads of Partners in Health Drs. Sheila Davis & John Welch on how they are bringing their expertise battling Ebola in West Africa to defeating the COVID-19 epidemic in Massachusetts. They explore precisely how and why tracing is an essential element in battling the epidemic.

Conquering COVID-19: When and From Where Will Vaccines and Therapies Emerge?

/
This week on Hubwonk, Host Joe Selvaggi is joined by Pioneer’s Bill Smith, Visiting Fellow in Life Sciences, and Dr. Peter Kolchinsky, Harvard-trained virologist, biotech investor and author of the new book, The Great American Drug Deal, to learn how the SARS-CoV2 works, what a vaccine may look like, and how we might produce it to scale.